

## Research Progress on Risk Factor in Childhood Asthma: A Systematic Review

Ibne Amin<sup>1\*</sup>, CHU ZhongXia<sup>2</sup>, Ikram Ul Haq<sup>3</sup>, Iftikhar Ullah<sup>4</sup>

<sup>1</sup>School of Clinical Medicine, Inner Mongolia University for the nationalities, 536 West Huo Lin He Street, Horqin District, Tongliao City, Inner Mongolia, P.R China.

\*Corresponding author

<sup>2</sup>Department of Pediatrics, Affiliated Hospital of Inner Mongolia University for the Nationalities, 1742 Huo Lin He Street, Horqin District, Tongliao City, Inner Mongolia, P.R China.

<sup>3</sup>School of Clinical Medicine, Inner Mongolia University for the nationalities, 536 West Huo Lin He Street, Horqin District, Tongliao City, Inner Mongolia, P.R China.

<sup>4</sup>Xian Jiaotong Medical University, 28 Xianning W Road, Jiaoda Commerce Block, Beilin, Xian, Shaanxi, P.R China.

Received: February 2021

Accepted: March 2021

### Abstract

**Background:** Childhood asthma is complex heterogeneous disorder with multiple factors involved in its causation. The basic aim of the study was to accomplish the systemic review of literature elucidating the recent research on risk factors of childhood asthma and its challenging therapies. **Methods:** Data sources: The data for this systematic review was collected from three databases namely PubMed, Science direct and Scopus was used to recoup papers examining the risk factor of childhood asthma and related research progress published from 2011 to 2020. All the included references were manually checked and children under 18 years were part of the study. Inclusion criteria: The studies included were original publication in English, meta-analysis, cross-sectional studies, and cohort/case-control studies. The main study interest was a risk factor of childhood asthma/wheeze and targeted folk was under eighteen children. The keywords used to find the relevant literature were asthma risk factor, asthma, childhood asthma, childhood asthma risk factor, childhood asthma prevention, and asthma therapy. **Results:** Initially, 1051 papers were collected by searching with help of different websites using keywords, and 977 papers were rejected due to irrelevant titles, abstracts, different age groups, and inappropriate estimates. 74 papers were found relevant abstracts which were further studies and more 43 papers were rejected. Finally, 31 papers were met the exact selection criteria. Twenty-two cross-sectional studies, five meta-analyses, and three cohort base studies. Typically increase in risk factor was noticed with OR= 0.60-3.35. **Conclusion:** Multiple factors are associated with childhood asthma, some of them have a positive effect and few have a role in reducing asthma in childhood. Currently, biomarkers are used to assess the disease and for quality treatment but limited numbers of markers can be used in clinical practice for pediatric patients these are blood and sputum eosinophils, serum IgE, periostin, and FeNO, they may be used individual or in combination for better response.

**Keywords:** Asthma, Childhood Asthma, Risk Factor, Analysis

### INTRODUCTION

Globally chronic disorder asthma is well known respiratory disorder with lethal effects on the health of every age group and has a major contribution to

increasing the burden of disease.<sup>[32]</sup> Prevalence of asthma is high in United states as 24 million people are facing asthma.<sup>[41]</sup> In United states asthma prevalence rate has been raised and affect the 3.1% in 1989, 8.3% of the

population was recorded in 2016.<sup>[42]</sup> African Americans living in less developed areas are more prone to an asthma attack while it is also deemed as a worse leading chronic disorder in children.<sup>[43]</sup> There is a censorious need to tailor asthma more persuasively. Asthma is a multifactorial and heterogeneous disorder associated with many genetic and environmental factors. Global initiative for asthma has conceded the pathophysiological, clinical, and demographical properties that are a pack of obvious asthma phenotypes namely allergic, non-allergic, and late-onset asthma.<sup>[44,45]</sup> Alteration of environmental exposure is one of the leading causes of developing high prevalence of asthma in the western world.<sup>[46]</sup> However, few exposures are probable to be important by means of epigenetic mechanism.<sup>[47]</sup> Asthma might be caused to various environmental exposure likely smoking, respiratory infections<sup>48</sup>, and multiple dietary factors.<sup>49</sup> Lately, much evidence has been concluded the asthma is the causation of interaction among different risk factors.<sup>[50]</sup> Two domains such as risk and impairment are clearly defined in present guidelines to control asthma, the term risk used to evaluate the assessment of asthma attacks, medication side effects, and disease development.<sup>[33,35]</sup> we can overcome the burden of asthma in children by reducing the asthma attacks and lifelong adverse findings of childhood asthma.<sup>[36,37]</sup> The main focus of research on long-lasting outcomes of childhood asthma specifically day by day step toward poorly control, severe asthma with irreversible damage of

lung function.<sup>[38]</sup> As the progress of technology with the advancement in treatment methodology and discovery of new medicines and new biomarkers provided new opportunities to developed technology-oriented individualized treatment strategies. In this way, we can reduce asthma attack and their lifelong effects on an individual's life.<sup>[39,40]</sup>

## **MATERIALS AND METHODS**

### **Data sources**

The data for this systematic review was collected from three databases namely PubMed, Science Direct and Scopus were used to recoup papers examining the risk factor of childhood asthma and related research progress published from 2011 to 2020. All the included references were manually checked and children under 18 years were the part of the study.

### **Inclusion criteria**

The studies included were original publication in English, meta-analysis, cross-sectional studies, and cohort/case-control studies. The main study interest was a risk factor of childhood asthma/wheeze and targeted folk was under eighteen children. The keywords used to find the relevant literature were asthma risk factor, asthma, childhood asthma, childhood asthma risk factor, childhood asthma prevention, and asthma therapy. All included studies were explained through outcomes and data (odd ratio =OR).



## RESULTS

An overview of selection criteria is given in [Figure1]. Initially, 1051 papers were collected by searching with help of different websites using keywords, and 977 papers were rejected due to irrelevant titles, abstracts, different age groups, and inappropriate estimates. 74 papers were found relevant abstracts which were further studies and more 43 papers were rejected. Finally, 31 papers were met the exact selection criteria. Twenty-two cross-sectional studies, five meta-analyses, and three cohort base studies. These selected studies were explained with different risk facts and interventions in [Table1-3].

### Association of different factors with childhood asthma

#### Exposure to pet animals

Three cross-sectional was identified included one study investigated the risk of asthma during infancy by exposing to indoor pets and found inverse association with risk of asthma (OR value 0.60, 95% CI 0.38-0.96). Exposure to dogs during the initial years of life may increase the risk of allergic rhinitis while cats may reduce the risk of atopic eczema.<sup>[2]</sup> Similarly, one more study was found with the same findings.<sup>[3]</sup> Controversy was exists in one publication between the children of school-going age 6-18 years that exposure to cats enhanced risk of asthma and such an environment highly exposed to dogs had a greater contribution to the prevalence of allergy in children.<sup>[1]</sup>

#### Exposure to air pollutants

Three cohort study and a meta-analysis was clearly indicated the association with asthma, not one pollutant responsible for asthma. Authors in meta-analysis demonstrated that A higher prevalence of asthma was found in children who had greater exposure to carbon monoxide, nitrogen dioxide, and nitric oxide with variation in odd ratio 1.06, 1.05, and 1.02 respectively, while exposure to Sulphur dioxide (OR = 1.04) triggers the wheeze in children.<sup>[4]</sup> One cohort study evaluates the exposure to nitrogen dioxide and sulfur dioxide with 2.5 and 10 micrometers, particulate matter and finding shows that higher exposure to an average increase of NO<sub>2</sub> 5 ppb trigger the asthma risks with confidence intervals 95% CI = 1.04-1.31.<sup>[5]</sup> Second study revealed that less the association was observed with asthma in children of age seven years when they had lifelong exposure to different gases including CO, NO<sub>2</sub>, SO<sub>2</sub>. Asthma risks were found twice in patients with bronchiolitis with excessive exposure to these gases.<sup>[6]</sup> Third cohort study was attempted that lifelong exposure to traffic particles had a potent association to develop asthma (OR= 1.25) in children of 0 to 5 years.<sup>[7]</sup>

#### Parental smoking

Two meta-analysis was identified associated with asthma, one study elucidated postnatal passive smoking had elevated the 30 to 70% chances of incidence of wheezing promptly in children age less than 2 years (OR = 1.70). The findings of this meta-analysis

concluded that parental smoking had increased the 20% incidence rate of asthma and wheezing in children.<sup>[8]</sup> Second meta-analysis concluded that maternal smoking was also linked with risk development of wheezing or asthma in children age six years (OR = 1.3) and data of school-going children was limited. Postnatal had no association with asthma and wheeze.<sup>[9]</sup>

### **Dietary exposure**

Three studies were identified including a case study of 1276 children including 300 asthma patients concluded that consumption of dairy products 3 to 6 times a week strongly associated with asthma with OR= 0.14 while consumption of meat and nuts daily and double in a week may be significantly linked with asthma. Children of age 3-6 were found less susceptible than 7-13 years to asthma (OR = 3.35), boys were more vulnerable to developed asthma risks (OR= 0.68).<sup>[10]</sup> A prospective cohort-based study on children of Netherlands by exposing them to a western diet for a duration of 14 months found an increase in association with wheeze at three years.<sup>[11]</sup> Early introducing fruits to children may decrease the risk to develop asthma at 8 years and by improving the plasma vitamin D could also reduce asthma risk with an OR value of 3.05 while serum vitamin D level had no association with the risk of asthma.<sup>[12]</sup>

### **Exposure to Infection**

The findings of two studies and one meta-analysis were collected, first, one prospective cohort study concluded

that upper respiration did not impose adverse respiratory effect as compared to children with a lower respiratory infection. Children of age 3 to 6 years suffering from lower respiratory infection were more prone to asthma risk (OR = 3.53).<sup>[13]</sup> the second study outcomes were indicated the strong relationship between early-life respiratory syncytial virus infection and worse respiratory outcomes in children of 0 to 12 years. Infectious child had (OR =3.05, CI = 2.50-3.71) recurrent wheezing and subsequently developed asthma.<sup>[15]</sup> Meta-analysis consist of 15 original articles and 4 cohort studies concluded that suffering from rhinovirus wheezing during infancy escalate the incident (relative risk, RR = 2.00) of asthma and wheezing in later life.<sup>[14]</sup>

### **Medication and asthma**

Three publications were elucidated the association of asthma with medicine. The use of antibiotics during prenatal conditions enhances the risk factors to develop asthma OR = 3.1 in children as compared to wheezing had OR value of 1.8 but the use of antibiotics during 1st trimester had no association with asthma and wheezing.<sup>[16]</sup> Paracetamol was not associated with asthma risk in children.<sup>[17]</sup> On the other hand Use of paracetamol for 6 months child could develop asthma at 3 years relative risk = 1.13) but not found at 7 years child.<sup>[18]</sup>

### **Therapeutic interventions**


Three studies related to inhaled corticosteroids recommend lower doses in children to prevent any harmful effect two studies on long-acting beta-

agonists which cause the relaxation of smooth muscle in the airway, and recommend the use of LABA in combination with ICS to overcome its adverse effects.<sup>[25-29]</sup> Two studies about leukotriene modifier especially for patients who had greater exposure to smoke.<sup>[30,31]</sup>

### Asthma therapy with biomarkers

Five studies, four articles, and one meta-analysis results were presented in [Table2]. Two biomarkers blood eosinophil count  $>300/\mu\text{L}$  and aeroallergen sensitization was used with three medicines and found efficacious control results of ICS in preschool children.<sup>[19]</sup> Eosinophilic asthma was diagnosed by using serum eosinophils and sputum eosinophils to target the environmental allergen asthma.<sup>[20]</sup> One meta-analysis support sputum eosinophil could be a better option to treat asthmatic patients. Two studies were about periostin as a

biomarker in pediatric asthma.<sup>[22,23]</sup> An Cochrane review was explained the FeNO effectiveness as a biomarker for children.<sup>[24]</sup>



**Figure 1: the flow diagram of literature selection process**

**Table 1: Characteristic of studies included in systematic review**

Factors	Authors	Age	Findings
Exposure to pet animals (cats and dogs)	Ojwang et al., 2020 Fretzayas et al., 2013. <sup>[2,3]</sup>	5 years	High association with OR value 0.60, 95% CI 0.38-0.96
	Song et al., 2014. <sup>[1]</sup>	6-18 years	Exposure to cats increased the prevalence of asthma and dogs had a contribution to allergy in children
Exposure to air pollutant (carbon mono oxide, nitrous oxide and nitrogen dioxide)	Gasana et al., 2012. <sup>[4]</sup>	0-16 years	Air pollutants had a strong impact on raising the prevalence of childhood asthma. The odd ratio for nitrous oxide, nitrogen dioxide and carbon mono oxide was 1.02, 1.05, and 1.06 respectively. While SO <sub>2</sub> was 1.04.
	Nishimura et al 2013. <sup>[5]</sup>	First few years of life	Increase of exposure to an average increase of NO <sub>2</sub> 5 ppb trigger the asthma risks with confidence intervals



			95% CI = 1.04- 1.31
	Kim et al., 2013. <sup>[6]</sup>	7 years	Higher interaction with ozone may enhance the past episodes of bronchiolitis and escalate the chances of asthma in children.
	Patel et al., 2011. <sup>[7]</sup>	0-5 years	Children could be at greater risk to develop asthma with OR 1.25 when they were exposed to higher traffic density.
Parental smoking	Burke et al., 2012. <sup>[8]</sup>	0-2 years	Postnatal smokers child were 30 to 70% at risk to develop wheezing (OR = 1.70) and parental smoking increased 20% incidence of asthma and wheeze in children.
	Silvestr et al., 2015. <sup>[9]</sup>	1.5-16 years	Maternal smoking-induced the risk of asthma and wheezing in children age six years with an odd ratio value of 1.3 and no association of asthma and wheeze was found with postnatal smoking.
Dietary exposure	Hallit et al., 2018. <sup>[10]</sup>	3-16 years	Consumption of dairy product 3 to 6 times a week strongly associated with asthma with OR= 0.14, Children of age 3-6 were found less susceptible than 7-13 years to asthma (OR = 3.35), boys were more vulnerable to developed asthma risks (OR= 0.68).
	Tromp et al., 2011. <sup>[11]</sup>	6 months -4 years	Exposure to the western diet may increase the risk of asthma
	Van et al., 2011. <sup>[12]</sup>	2-8 years	Early life introducing fruits to children may decrease the risk to develop asthma at 8 years and by improving the plasma vitamin D could also, reduce asthma risk with OR value 3.05 while serum vitamin D level had no association with risk of asthma.
Exposure to Infection	Van et al., 2018. <sup>[13]</sup>	>3-6 years	Early-life exposure to the lower respiratory tract infection consistently lowering the lungs function and increased the asthma risk. (OR= 3.53)
	Liu et al., 2017. <sup>[14]</sup>	0-3 years	In the first three years of life rhinovirus wheezing illness could escalate the risk of wheezing and asthma in adult age. (relative risk, RR = 2.00)

	Shi et al., 2020. <sup>[15]</sup>	0-12 years	Respiratory syncytial virus infection and worse respiratory outcomes in children of 0 to 12 years. The infectious child had (OR =3.05, CI = 2.50-3.71) recurrent wheezing and subsequently developed asthma
Medication and asthma	Lapin et al., 2015. <sup>[16]</sup>	0-1 year	Use of prenatal antibiotic enhance the risk factor to develop asthma OR = 3.1 in children as compared to wheezing had OR value of 1.8 but the use of antibiotic during 1st trimester had no association with asthma and wheezing
	Magnus et al., 2018	0-7 years	Use of paracetamol for 6 months child could develop asthma at 3 years (relative risk = 1.13) but not found at 7 years child.
	Heintze et al., 2013	0-5 years	The use of paracetamol had no association in development of wheezing and asthma

**Table 2: Role of biomarkers**

Authors, year	Studies	Findings
Fitzpatrick et al., 2016. <sup>[19]</sup>	Asthma therapy with biomarkers (Children were treated with asthma controller medication inhaled daily for 2-8 weeks treatment included corticosteroids, leukotriene receptor antagonists. The response of ICS was targeted through two biomarkers, blood eosinophil count >300/ $\mu$ L and aeroallergen sensitization)	In all treatments best control results for asthma were obtained from ICS used with eosinophil blood count. 42% positive response of aeroallergen sensitized.
deGroot et al., 2015. <sup>[20]</sup>	Serum and sputum eosinophils was used to diagnose asthma caused by environmental factors.	Sputum eosinophila was found more efficacious as compared to the serum which could be used as a substitute of sputum eosinophila
Petsky et al., 2012. <sup>[21]</sup>	Compare the inhale corticosteroid, FeNO treatment, and sputum eosinophil in children and adults.	Asthma treatment in children based on sputum eosinophil with ICS shows the effective results rather than FeNO treatment
Scichilone et al., 2016. <sup>[22]</sup> Anderson et al., 2017. <sup>[23]</sup>	IgE level and serum periostin level was used as a biomarker in children of age 2, 6 and 11 years to determine the early childhood asthma initiation.	Periostin as biomarker found more frequent for asthma and high level of periostin in children was due to bone

		turnover.
Petsky et al., 2016. <sup>[24]</sup>	Fractional exhaled nitric oxide was deemed as a marker to optimize the treatment and may reduce the asthma exacerbations.	The level of FeNO was not effectively associated with asthma therapy in children so, it should recommend as asthma guide therapy

**Table 3: Different studies finding in treatment of childhood asthma**

Therapeutic interventions	Authors	Findings
Corticosteroids	Boulet et al., 2019. <sup>[25]</sup>	ICS can be used to treat the acute asthma but in children, it could suppress the hypothalamic-pituitary adrenal axis because of its prolonged treatment.
	Lombard et al., 2012. <sup>[26]</sup>	Evidence support that children treated with a lower dosage of inhaled corticosteroids suffered from suppression of hypothalamic pituitary adrenal axis.
	Issa et al., 2015. <sup>[27]</sup>	Pediatric patients treated for six months with a high dose of ICS were found with adrenal suppression.
Long-acting beta agonists (LABA)	Scott et al., 2012. <sup>[28]</sup>	LABU must use in combination with ICS. The use of LABA alone imposed adverse effects on pediatric patients by increasing the risk of asthma leading to death.
	Busse et al., 2018. <sup>[29]</sup>	To treat the various asthma endo types use the LABA in combination with ICS was found more effective in children.
Leukotriene modifier	Pacheco et al., 2014. <sup>[30]</sup> Marcello et al., 2016. <sup>[31]</sup>	Efficacious results of leukotriene modifiers were obtained for the patients who exposed to smoke. It was also found effective for patients with asthma small airway disease

## DISCUSSION

The aim of this systematic review was to collect recent literature on risk factors of childhood asthma and to determine the research progress to treat asthma in children. This study was based on observational studies and found the literature on exposure to environmental factors, tobacco, respiratory infection, and dietary factors. All these factors have an indispensable role in the development of asthma. Exposure of pre-school

children to pet animals had an association with asthma that might be suspected to develop asthma at 6 years.<sup>[71,72]</sup> Pediatric asthma had linked with air pollutants as exposure to air pollutant elevate the risk of asthma and eczema in children.<sup>[73,74]</sup> Child respiratory disease asthma was linked with parents indoor smoking as well as outdoor smoking.<sup>[75]</sup> children were more prone to asthma in case of greater exposure to smoke odor.<sup>[76]</sup> Although a complex relationship exists between various dietary factors and asthma risk,



a child who took the exclusive breastfeeding for 6 months was less vulnerable to asthma.<sup>[77]</sup> Prolong breastfeeding did not any adverse effect and no association with asthma.<sup>[78]</sup>

Secondly, we collected the literature on the therapeutic intervention of asthma that mainly focused on the use of biomarkers and other treatments. Biological markers are indicators that help to assess the disease and measured in an appropriate analytical test system.<sup>[51]</sup> Biomarkers used in asthma treatment are elucidated above and biological specimens were used to measure asthma in children such as sputum, blood, inhaled breath condensate.<sup>[52]</sup> However, the most recently used few golden standards to approach the inflammation and remodeling in asthma are bronchial biopsy and BAL with bronchoscopy. Its use for pediatric diagnosis is limited due to adverse effects.<sup>[53,54]</sup> the use of sputum induction was also found limited especially in children because of the complex method and invasive in nature.<sup>[55]</sup> now researcher trying to make sure availability of non-invasive childhood asthma markers to diagnosed the inflammation. Potentially biomarkers of asthma can be used to distinguish the inflammatory endo-type (T2- cytokine targeted therapy) that successfully assess and monitor the disease progression.<sup>[56-58]</sup> In pre-school children FeNO can be used as a predictive factor of new pediatric patients,<sup>[79]</sup> it is considered a surrogate marker to identify asthma in children.<sup>[80]</sup> In the case of severe asthma, biomarkers

could be used in combination or single to assess the severity of the disease.

The current inception of biomarkers includes the sputum eosinophils, serum IgE, periostin, and FeNO.<sup>[59-61]</sup> Eosinophils are a central driver of T2 inflammation in children with severe asthma and had a critical role in chronic inflammation.<sup>[62-66]</sup> A better response of ICS therapy was indicated with the presence of blood eosinophilia and high FeNO, although the poor response was measured for oral corticosteroid therapy.<sup>[67,68]</sup> One more study concluded that the best predictor response to ICS was obtained through the blood eosinophil count and aeroallergen sanitization in preschool children,<sup>[69]</sup> such finding helped to tailor treatment of preschool asthma children.<sup>[70]</sup>

## CONCLUSION

Childhood asthma deemed a challenging disease as it has various endo-types. Multiple factors are associated with childhood asthma, some of them have positive effects and few have a role in reducing asthma in childhood. Currently, biomarkers are used to assess the disease and for quality treatment but limited numbers of markers can be used in clinical practice for pediatric patients these are blood and sputum eosinophils, serum IgE, periostin, and FeNO, they may be used individual or in combination for better response.



## REFERENCES

1. Song N, Mohammed S, Zhang J, et al. Prevalence, severity and risk factors of asthma, rhinitis and eczema in a large group of Chinese schoolchildren. *J Asthma*. 2014;51(3):232-242.
2. Ojwang, V., Nwaru, B. I., Takkinen, H. M., Kaila, M., Niemelä, O., Haapala, A. M., ... & Virtanen, S. M. (2020). Early exposure to cats, dogs and farm animals and the risk of childhood asthma and allergy. *Pediatric Allergy and Immunology*, 31(3), 265-272.
3. Fretzayas A, Kotzia D, Moustaki M. Controversial role of pets in the development of atopy in children. *World J Pediatr*. 2013;9(2):112-119.
4. Gasana J, Dillikar D, Mendy A, et al. Motor vehicle air pollution and asthma in children: a meta-analysis. *Environ Res* 2012;117:36-45.
5. Nishimura KK, Galanter JM, Roth LA, et al. Early-life air pollution and asthma risk in minority children. The GALA II and SAGE II studies. *Am J Respir Crit Care Med* 2013;188:309-18.
6. Kim BJ, Seo JH, Jung YH, et al. Air pollution interacts with past episodes of bronchiolitis in the development of asthma. *Allergy* 2013;68:517-23.
7. Patel MM, Quinn JW, Jung KH, et al. Traffic density and stationary sources of air pollution associated with wheeze, asthma, and immunoglobulin E from birth to age 5 years among New York City children. *Environ Res* 2011;111:1222-9.
8. Burke H, Leonardi-Bee J, Hashim A, Pine-Abata H, Chen Y, Cook DG, Britton JR, McKeever TM. Prenatal and passive smoke exposure and incidence of asthma and wheeze: systematic review and meta-analysis. *Pediatrics*. 2012 Apr 1;129(4):735-44.
9. Silvestri M, Franchi S, Pistorio A, Petecchia L, Rusconi F. Smoke exposure, wheezing, and asthma development: a systematic review and meta-analysis in unselected birth cohorts. *Pediatric pulmonology*. 2015 Apr;50(4):353-62.
10. Hallit S, Raherison C, Abou Abdallah R, Hallit R, Salameh P. Correlation of types of food and asthma diagnosis in childhood: A case-control study. *Journal of Asthma*. 2018 Sep 2;55(9):966-74.
11. Tromp II, Kiefte-de Jong JC, Lebon A, et al. The introduction of allergenic foods and the development of reported wheezing and eczema in childhood: the Generation R study. *Arch Pediatr Adolesc Med* 2011;165:933-8.
12. van Oeffelen AA, Bekkers MB, Smit HA, et al. Serum micronutrient concentrations and childhood asthma: the PIAMA birth cohort study. *Pediatr Allergy Immunol* 2011;22:784-93.
13. Van Meel ER, Den Dekker HT, Elbert NJ, Jansen PW, Moll HA, Reiss IK, De Jongste JC, Jaddoe VW, Duijts L. A population-based prospective cohort study examining the influence of early-life respiratory tract infections on school-age lung function and asthma. *Thorax*. 2018 Feb 1;73(2):167-73.
14. Liu L, Pan Y, Zhu Y, Song Y, Su X, Yang L, Li M. Association between rhinovirus wheezing illness and the development of childhood asthma: a meta-analysis. *BMJ open*. 2017 Apr 1;7(4):e013034.
15. Shi T, Ooi Y, Zaw EM, Utjesanovic N, Campbell H, Cunningham S, Bont L, Nair H. Association between respiratory syncytial virus-associated acute lower respiratory infection in early life and recurrent wheeze and asthma in later childhood. *The Journal of infectious diseases*. 2020 Nov 1;222(Supplement\_7):S628-33.
16. Lapin B, Piorkowski J, Ownby D, Freels S, Chavez N, Hernandez E, Wagner-Cassanova C, Pelzel D, Vergara C, Persky V. Relationship between prenatal antibiotic use and asthma in at-risk children. *Annals of Allergy, Asthma & Immunology*. 2015 Mar 1;114(3):203-7.
17. Heintze K, Petersen KU. The case of drug causation of childhood asthma: antibiotics and paracetamol. *Eur J Clin Pharmacol* 2013;69:1197-209.
18. Magnus MC, Karlstad Ø, Håberg SE, Nafstad P, Davey Smith G, Nystad W. Prenatal and infant paracetamol exposure and development of asthma: the Norwegian Mother and Child Cohort Study. *International journal of epidemiology*. 2016 Apr 1;45(2):512-22.
19. Fitzpatrick AM, Jackson DJ, Mauger DT, et al. Individualized therapy for persistent asthma in young children. *J Allergy Clin Immunol*. 2016;138(6):1608-1618.e1612.
20. deGroot JC, Ten Brinke A, Bel EH. Management of the patient with eosinophilic asthma: a new era begins. *ERJ open research*. 2015 May 1;1(1).



21. Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA, Chang AB. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). *Thorax*. 2012 Mar 1;67(3):199-208.
22. Scichilone N, Crimi C, Benfante A, Battaglia S, Iemmolo M, Spatafora M, Crimi N. Higher serum levels of periostin and the risk of exacerbations in moderate asthmatics. *Asthma research and practice*. 2016 Dec;2(1):1-5.
23. Anderson HM, Lemanske Jr RF, Arron JR, Holweg CT, Rajamanickam V, Gangnon RE, Gern JE, Jackson DJ. Relationships among aeroallergen sensitization, peripheral blood eosinophils, and periostin in pediatric asthma development. *Journal of Allergy and Clinical Immunology*. 2017 Mar 1;139(3):790-6.
24. Petsky HL, Kew KM, Chang AB. Exhaled nitric oxide levels to guide treatment for children with asthma. *Cochrane Database of Systematic Reviews*. 2016(11).
25. Boulet LP, Reddel HK, Bateman E, Pedersen S, FitzGerald JM, O'Byrne PM. The global initiative for asthma (GINA): 25 years later. *European Respiratory Journal*. 2019 Aug 1;54(2).
26. Lombard, C. J., U. Galal, F. S. Hough, E. Irusen, and E. Weinberg. "Hypothalamic-pituitary-adrenal axis suppression in asthmatic school children." (2012).
27. Issa-El-Khoury K, Kim H, Chan ES, Vander Leek T, Noya F. CSACI position statement: systemic effect of inhaled corticosteroids on adrenal suppression in the management of pediatric asthma. *Allergy, Asthma & Clinical Immunology*. 2015 Dec;11(1):1-4.
28. Scott DR, Laubach S. Age and Risks of FDA-Approved Long-Acting  $\beta$ 2-adrenergic Receptor Agonists. *Pediatrics*. 2012 Oct 1;130(Supplement 1):S41-2.
29. Busse WW, Bateman ED, Caplan AL, Kelly HW, O'Byrne PM, Rabe KF, Chinchilli VM. Combined analysis of asthma safety trials of long-acting  $\beta$ 2-agonists. *New England Journal of Medicine*. 2018 Jun 28;378(26):2497-505.
30. Pacheco Y, Freymond N, Devouassoux G. Impact of montelukast on asthma associated with rhinitis, and other triggers and comorbidities. *Journal of Asthma*. 2014 Feb 1;51(1):1-7.
31. Marcello C, Carlo L. Asthma phenotypes: the intriguing selective intervention with Montelukast. *Asthma research and practice*. 2016 Dec;2(1):1-2.
32. Masoli M, Fabian D, Holt S, Beasley R, for the Global Initiative for Asthma (GINA). Global burden of asthma (2004). [http://www.ginasthma.org/local/uploads/files/GINABurdenReport\\_1.pdf](http://www.ginasthma.org/local/uploads/files/GINABurdenReport_1.pdf) (accessed March 17, 2015).
33. Buhl R, Bals R, Baur X, et al. Guideline for the diagnosis and treatment of asthma - guideline of the German respiratory society and the German Atemwegsliga in cooperation with the paediatric respiratory society and the Austrian society of pneumology. *Pneumologie*. 2017;71(12):e3.
34. Global Initiative for Asthma. Global strategy for asthma management and prevention (2019 report). <https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf>. 2019. Accessed October 29, 2019.
35. Scottish Intercollegiate Guidelines Network, British Thoracic Society. British guideline on the management of asthma. <https://www.britthoracic.org.uk/document-library/guidelines/asthma/btssi-gn-guideline-for-the-management-of-asthma-2019/>. 2019. Accessed October 29, 2019.
36. Szeffler SJ. Asthma across the lifespan: time for a paradigm shift. *J Allergy Clin Immunol*. 2018;142(3):773-780.
37. Szeffler SJ. Boehringer Ingelheim satellite symposium. Choosing the right controller therapy in pediatric patients with asthma. *Pediatr Pulmonol*. 2018;53(S1):S171-S173.
38. McGeachie MJ, Yates KP, Zhou X, et al. Patterns of growth and decline in lung function in persistent childhood asthma. *N Engl J Med*. 2016;374(19):1842-1852.
39. Belgrave DC, Buchan I, Bishop C, Lowe L, Simpson A, Custovic A. Trajectories of lung function during childhood. *Am J Respir Crit Care Med*. 2014;189(9):1101-1109.
40. Petsky HL, Cates CJ, Kew KM, Chang AB. Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis. *Thorax* 2018;73(12):1110-1119.
41. National Center for Health Statistics. National Health Interview Survey, 2016. Public-use data



- file and documentation.  
[http://www.cdc.gov/nchs/nhis/quest\\_data\\_related\\_1997\\_forward.htm](http://www.cdc.gov/nchs/nhis/quest_data_related_1997_forward.htm). 2018.
42. Global Initiative for Asthma, National Heart Lung and Blood Institute. Global initiative for asthma: global strategy for asthma management and prevention (2016 update). Bethesda, MD: U.S. Dept. of Health and Human Services, Public Health Service; 2016.
43. World Health Organization. Genetics and asthma: World Health Organization; [Available from: <http://www.who.int/genomics/about/Asthma.pdf> accessed April 4 2018.
44. Kim SH, Choi H, Yoon MG, et al. Dipeptidyl-peptidase 10 as a genetic biomarker for the aspirin-exacerbated respiratory disease phenotype. *Ann Allergy Asthma Immunol* 2015;114(3):208-13.
45. Muscat P, Mercado K, Payne K, et al. PHF11 expression and cellular distribution is regulated by the toll-like receptor 3 ligand polyinosinic polycytidylic Acid in HaCaT keratinocytes. *BMC Immunol* 2015;16:69.
46. Kozyrskyj AL, Bahreinian S, Azad MB. Early life exposures: impact on asthma and allergic disease. *Curr Opin Allergy Clin Immunol* 2011;11:400-6.
47. Le Cann P, Bonvallot N, Glorennec P, et al. Indoor environment and children's health: recent developments in chemical, biological, physical and social aspects. *Int J Hyg Environ Health* 2011;215:1-18.
48. Bloomberg GR. The influence of environment, as represented by diet and air pollution, upon incidence and prevalence of wheezing illnesses in young children. *Curr Opin Allergy Clin Immunol* 2011;11:144-9.
49. Dick S, Doust E, Cowie H, et al. Associations between environmental exposures and asthma control and exacerbations in young children—a systematic review. *BMJ Open* 2014;4:e003827.
50. Neuman A, Hohmann C, Orsini N, et al. Maternal smoking in pregnancy and asthma in preschool children: a pooled analysis of eight birth cohorts. *Am J Respir Crit Care Med* 2012;186:1037-43.
51. Jochmann A, Artusio L, Robson K, Nagakumar P, Collins N, Fleming L, et al. Infection and inflammation in induced sputum from preschool children with chronic airways diseases. *Pediatr Pulmonol* 2016; 51:778-786.
52. Akdis CA, Agache I. *Global Atlas of Asthma*. Zurich, Switzerland: European Academy of Allergy and Clinical Immunology, 2013, pp. 34-35.
53. Vijverberg SJ, Hilvering B, Raaijmakers JA, Lammers JW, Maitland-van der Zee AH, Koenderman L. Clinical utility of asthma biomarkers: from bench to bedside. *Biologics* 2013; 7:199-210.
54. Moschino L, Zanconato S, Bozzetto S, Baraldi E, Carraro S. Childhood asthma biomarkers: present knowledge and future steps. *Paediatr Respir Rev* 2015; 16:205-212.
55. Bandyopadhyay A, Roy PP, Saha K, Chakraborty S, Jash D, Saha D. Usefulness of induced sputum eosinophil count to assess severity and treatment outcome in asthma patients. *Lung India: official organ of Indian chest society*. 2013 Apr;30(2):117.
56. Zissler UM, Esser-von Bieren J, Jakwerth CA, Chaker AM, Schmidt-Weber CB. Current and future biomarkers in allergic asthma. *Allergy* 2016; 71:475-494.
57. Cosmi L, Liotta F, Maggi L, Annunziato F. Role of type 2 innate lymphoid cells in allergic diseases. *Curr Opin Allergy Clin Immunol* 2017; 17:66.
58. Fahy JV. Type 2 inflammation in asthma—present in most, absent in many. *Nat Rev Immunol* 2015;15:57-65.
59. Robinson D, Humbert M, Buhl R, Cruz AA, Inoue H, Korom S, et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. *Clin Exp Allergy* 2017; 47:161-175.
60. Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. *Clin Exp Allergy* 2012; 42:650-658.
61. Lo'tvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. *J Allergy Clin Immunol* 2011; 127:355-360.
62. Bossley CJ, Fleming L, Gupta A, Regamey N, Frith J, Oates T, et al. Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines. *J Allergy Clin Immunol* 2012; 129:974-982.e13.
63. Fitzpatrick AM, Moore WC. Severe asthma phenotypes—how should they guide evaluation and treatment? *J Allergy Clin Immunol Pract* 2017; 5:901-908.



64. Wadsworth S, Sin D, Dorscheid D. Clinical update on the use of biomarkers of airway inflammation in the management of asthma. *J Asthma Allergy* 2011; 4:77-86.
65. Agache I, Rogozia L. Asthma biomarkers: do they bring precision medicine closer to the clinic? *Allergy Asthma Immunol Res* 2017; 9:466-476.
66. Zissler UM, Esser-von Bieren J, Jakwerth CA, Chaker AM, Schmidt-Weber CB. Current and future biomarkers in allergic asthma. *Allergy* 2016; 71:475-494.
67. Cowan DC, Taylor DR, Peterson LE, Cowan JO, Palmay R, Williamson A, et al. Biomarker-based asthma phenotypes of corticosteroid response. *J Allergy Clin Immunol* 2015; 135:877-883.e1
68. Akar HH, Tahan F, Gungor HE. The association of forced expiratory volume in one second and forced expiratory flow at 50% of the vital capacity, peak expiratory flow parameters, and blood eosinophil counts in exercise-induced bronchospasm in children with mild asthma. *Asia Pac Allergy* 2015; 5:98-102.
69. Fitzpatrick AM, Jackson DJ, Mauger DT, Boehmer SJ, Phipatanakul W, Sheehan WJ, et al. Individualized therapy for persistent asthma in young children. *J Allergy Clin Immunol* 2016; 138:1608-1618.e12.
70. Raissy H, Blake K. Personalized medicine in preschool children with asthma. *Pediatr Allergy Immunol Pulmonol* 2017; 30:260-262.
71. Fall T, Lundholm C, Örtqvist AK, Fall K, Fang F, Hedhammar Å, Kämpe O, Ingelsson E, Almquist C. Early exposure to dogs and farm animals and the risk of childhood asthma. *JAMA pediatrics*. 2015 Nov 1;169(11):e153219-.
72. Johnson CC, Ownby DR. The infant gut bacterial microbiota and risk of pediatric asthma and allergic diseases. *Translational Research*. 2017 Jan 1;179:60-70.
73. To T, Zhu J, Stieb D, Gray N, Fong I, Pinault L, Jerrett M, Robichaud A, Ménard R, van Donkelaar A, Martin RV. Early life exposure to air pollution and incidence of childhood asthma, allergic rhinitis and eczema. *European Respiratory Journal*. 2020 Feb 1;55(2).
74. Litonjua AA, Weiss ST. Risk factors for asthma. *UpToDate*. 2015.
75. Zhuge Y, Qian H, Zheng X, Huang C, Zhang Y, Li B, Zhao Z, Deng Q, Yang X, Sun Y, Zhang X. Effects of parental smoking and indoor tobacco smoke exposure on respiratory outcomes in children. *Scientific reports*. 2020 Mar 9;10(1):1-9.
76. He Z, Wu H, Zhang S, Lin Y, Li R, Xie L, Li Z, Sun W, Huang X, Zhang CJ, Ming WK. The association between secondhand smoke and childhood asthma: A systematic review and meta-analysis. *Pediatric Pulmonology*. 2020 Oct;55(10):2518-31.
77. Huang C, Liu W, Cai J, Weschler LB, Wang X, Hu Y, Zou Z, Shen L, Sundell J. Breastfeeding and timing of first dietary introduction in relation to childhood asthma, allergies, and airway diseases: a cross-sectional study. *Journal of Asthma*. 2017 May 28;54(5):488-97.
78. Castro-Rodriguez JA, Forno E, Rodriguez-Martinez CE, Celedón JC. Risk and protective factors for childhood asthma: what is the evidence?. *The Journal of Allergy and Clinical Immunology: In Practice*. 2016 Nov 1;4(6):1111-22.
79. Kotaniemi-Syrjänen A, Malmberg LP, Malmström K, Pelkonen AS, Mäkelä MJ. Factors associated with elevated exhaled nitric oxide fraction in infants with recurrent respiratory symptoms. *Eur Respir J* 2013; 41:189-194.
80. Gabriele C, Jaddoe VW, van Mastrigt E, Arends LR, Hofman A, Moll HA, et al. Exhaled nitric oxide and the risk of wheezing in infancy: the Generation R Study. *Eur Respir J* 2012; 39:567-572.

Source of Support: Nil, Conflict of Interest: None declared